Previous Close | 0.0250 |
Open | 0.0250 |
Bid | 0.0250 x N/A |
Ask | 0.0300 x N/A |
Day's Range | 0.0250 - 0.0250 |
52 Week Range | 0.0250 - 0.0600 |
Volume | |
Avg. Volume | 72,600 |
Market Cap | 3.032M |
Beta (5Y Monthly) | 0.95 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MOUNTAIN VIEW, Calif., October 03, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end.
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today. Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including
MOUNTAIN VIEW, Calif., August 29, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024.